Literature DB >> 12003810

Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent.

Somnath Mukhopadhyay1, Barry M Chapnick, Allyn C Howlett.   

Abstract

The endogenous cannabinoid anandamide (arachidonylethanolamide) produces vasorelaxation in different vascular beds. In the present study, we found that anandamide and a metabolically stable analog, methanandamide, produced dose-dependent (10 nM-10 microM) vasorelaxation of approximately 80% in a rabbit aortic ring preparation in an endothelium-dependent manner. Non-endothelium-dependent vasorelaxation was observed to be a maximum of 20-22% at >10 microM methanandamide. The efficacious CB(1) receptor analogs desacetyllevonantradol (10 microM) and WIN55212-2 (10 microM) failed to produce vasorelaxation; however, the endothelium-dependent vasorelaxation evoked by methanandamide was partially (75%) blocked by the CB(1) receptor antagonist SR141716A. The VR(1) vanilloid receptor antagonist capsazepine or the calcitonin gene-related peptide (CGRP) antagonist CGRP-(8-37) partially attenuated (25%) the vasorelaxation in endothelium-intact preparations and greatly reduced the response in endothelium-denuded preparations. Pretreatment of aortic rings with N(G)-nitro-L-arginine methyl ester completely blocked the methanandamide-, capsaicin-, and CGRP-induced vasorelaxation. Pretreatment of aortic rings with pertussis toxin attenuated the methanandamide-induced vasorelaxation in endothelium-intact aortic rings, indicating the involvement of G(i/o) proteins in the vasorelaxation; however, pertussis toxin treatment failed to block the endothelium-independent response. Thus, in the rabbit aorta, methanandamide-induced vasorelaxation exhibits two components: 1) in endothelium-intact rings, an SR141716A-sensitive, non-CB(1) receptor component that requires pertussis toxin-sensitive G proteins and nitric oxide (NO) production; and 2) in endothelium-denuded rings, a component that is mediated by VR(1) vanilloid receptors and possibly by the subsequent release of CGRP that requires NO production but is independent of pertussis toxin-sensitive G proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003810     DOI: 10.1152/ajpheart.00497.2001

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  36 in total

Review 1.  The complexities of the cardiovascular actions of cannabinoids.

Authors:  Michael D Randall; David A Kendall; Saoirse O'Sullivan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

2.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

Review 3.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 4.  Endocannabinoids in cerebrovascular regulation.

Authors:  Zoltán Benyó; Éva Ruisanchez; Miriam Leszl-Ishiguro; Péter Sándor; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-01-29       Impact factor: 4.733

5.  GPR55 and the vascular receptors for cannabinoids.

Authors:  C R Hiley; S S Kaup
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

6.  Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor.

Authors:  Pui Man Hoi; C Robin Hiley
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

7.  Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression.

Authors:  Markus Waldeck-Weiermair; Cristina Zoratti; Wolfgang F Graier; Karin Osibow; Nariman Balenga; Edith Goessnitzer; Maria Waldhoer; Roland Malli
Journal:  J Cell Sci       Date:  2008-04-29       Impact factor: 5.285

Review 8.  Endothelial atypical cannabinoid receptor: do we have enough evidence?

Authors:  Alexander I Bondarenko
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

9.  Increased angiotensin II contraction of the uterine artery at early gestation in a transgenic model of hypertensive pregnancy is reduced by inhibition of endocannabinoid hydrolysis.

Authors:  Victor M Pulgar; Liliya M Yamaleyeva; Jasmina Varagic; Carolynne M McGee; Michael Bader; Ralf Dechend; Allyn C Howlett; K Bridget Brosnihan
Journal:  Hypertension       Date:  2014-06-16       Impact factor: 10.190

10.  N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor.

Authors:  Douglas McHugh; Sherry S J Hu; Neta Rimmerman; Ana Juknat; Zvi Vogel; J Michael Walker; Heather B Bradshaw
Journal:  BMC Neurosci       Date:  2010-03-26       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.